Patent: 10,016,412
✉ Email this page to a colleague
Summary for Patent: 10,016,412
| Title: | TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs) |
| Abstract: | The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) and Toll-like receptor agonist (TLR) through a linker and a multifunctional connector group or molecule. |
| Inventor(s): | Spiegel; David (New Haven, CT), Fitzgerald; Kelly (New Haven, CT) |
| Assignee: | YALE UNIVERSITY (New Haven, CT) |
| Application Number: | 15/374,272 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,016,412
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Merck Teknika Llc | TICE BCG | bcg live | For Injection | 102821 | 06/21/1989 | ⤷ Try a Trial | 2021-05-01 |
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2021-05-01 |
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2021-05-01 | |
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2021-05-01 | |
| Hoffmann-la Roche Inc. | ROFERON-A | interferon alfa-2a | For Injection | 103145 | 06/04/1986 | ⤷ Try a Trial | 2021-05-01 |
| Clinigen, Inc. | PROLEUKIN | aldesleukin | For Injection | 103293 | 05/05/1992 | ⤷ Try a Trial | 2021-05-01 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
